Lawrence Kenyon

Mr. Kenyon serves as President, CEO and CFO of Outlook Therapeutics. Prior to that, Mr. Kenyon served as the CFO of Arno Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, and also as COO from July 2014 to September 2015. Mr. Kenyon served as the Interim President & CEO, CFO and Secretary of Tamir Biotechnology, Inc., a publicly held biopharmaceutical company engaged in the development of oncology and anti-infective therapeutics. Prior to that, Mr. Kenyon was the EVP, Finance and, commencing in March 2009, the CFO of, Par Pharmaceutical Companies, Inc., a publicly held generic and branded specialty pharmaceutical company, or Par. Prior to joining Par, Mr. Kenyon was the CFO and Secretary of Alfacell Corporation. Mr. Kenyon served as the EVP, CFO and Corporate Secretary at NeoPharm, Inc., a publicly traded biopharmaceutical company.